13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
148 檔
45.4%
During the Q4 2025 filing period, Ikarian Capital, LLC (CIK: 0001778253) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $928.2M across 148 reported positions.
Ikarian Capital, LLC executed strategic sector rebalancing during Q4 2025, establishing 47 new positions while fully exiting 38 holdings and trimming 62 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | Stock-Other | 9.89% | — | +106.42% | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 8.09% | -3.19% | +13.33% | |
| 3 | AMGN | Amgen Inc | Stock-Healthcare | 6.26% | — | — | |
| 4 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 5.04% | -11.37% | EXIT | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 3.59% | +10.00% | -16.41% | |
| 6 | HROW | Harrow Inc | Stock-Other | 2.65% | -0.93% | +139.23% | |
| 7 | RAPT | Rapt Therapeutics Inc | Stock-Other | 2.53% | — | +20.92% | |
| 8 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.30% | -6.65% | EXIT | |
| 9 | ✓ | Jazz Pharmaceuticals PLC | Stock-Other | 2.26% | — | +140.45% | |
| 10 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.16% | -0.94% | EXIT | |
| 11 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 2.13% | -0.19% | EXIT | |
| 12 | MAZE | Maze Therapeutics Inc | Stock-Other | 2.09% | +0.27% | -12.98% | |
| 13 | OMER | Omeros CORP | Stock-Other | 2.01% | — | — | |
| 14 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.99% | +1.51% | -32.66% | |
| 15 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.87% | -0.60% | — | |
| 16 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.83% | +4.52% | -30.77% | |
| 17 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 1.59% | — | — | |
| 18 | KOD | Kodiak Sciences Inc | Stock-Other | 1.57% | +1.13% | +73.93% | |
| 19 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.45% | -2.04% | EXIT | |
| 20 | PCVX | Vaxcyte Inc | Stock-Other | 1.36% | +0.41% | +18.83% | |
| 21 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.34% | — | -5.17% | |
| 22 | CAPR | Capricor Therapeutics Inc | Stock-Other | 1.30% | +0.31% | +24.40% | |
| 23 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.21% | -0.24% | +6.69% | |
| 24 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.16% | — | — | |
| 25 | LLY | Eli Lilly & Co | Stock-Healthcare | 1.16% | -0.49% | EXIT | |
| 26 | RLMD | Relmada Therapeutics Inc | Stock-Other | 1.16% | +0.08% | +66.48% | |
| 27 | ✓ | Connect Biopharma Hldgs LTD | Stock-Other | 1.09% | +0.06% | — | |
| 28 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.06% | — | -5.93% | |
| 29 | PHVS | Pharvaris N.V. | Stock-Other | 1.05% | +0.03% | +131.65% | |
| 30 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.97% | -0.32% | +933.12% | |
| 31 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.93% | -0.22% | +459.15% | |
| 32 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.92% | +0.38% | — | |
| 33 | SPRB | Spruce Biosciences Inc | Stock-Other | 0.83% | +0.07% | +810.26% | |
| 34 | CELC | Celcuity Inc | Stock-Other | 0.82% | — | — | |
| 35 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.78% | — | -50.94% | |
| 36 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.72% | +0.22% | +368.18% | |
| 37 | DXCM | Dexcom Inc | Stock-Healthcare | 0.71% | — | — | |
| 38 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 0.70% | — | -75.96% | |
| 39 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.68% | — | -26.79% | |
| 40 | CGON | Cg Oncology Inc | Stock-Other | 0.65% | — | -20.04% | |
| 41 | FBRX | Forte Biosciences Inc | Stock-Other | 0.64% | -0.20% | — | |
| 42 | PTHS | Pelthos Therapeutics Inc | Stock-Other | 0.62% | +0.34% | +309.53% | |
| 43 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.57% | — | — | |
| 44 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.54% | — | -8.77% | |
| 45 | ACOG | Alpha Cognition Inc | Stock-Other | 0.54% | +0.18% | +11.62% | |
| 46 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.51% | +0.23% | — | |
| 47 | IVVD | Invivyd Inc | Stock-Other | 0.51% | -0.03% | +27.80% | |
| 48 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 0.51% | +0.58% | — | |
| 49 | NUVL | Nuvalent Inc-a | Stock-Other | 0.47% | -0.20% | EXIT | |
| 50 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.40% | +0.02% | -9.62% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +7.2% | +106.42% | Add |
| 2 | 430 | Terns Pharmaceuticals Inc | +4.9% | +872.20% | Add |
| 3 | ✓ | Jazz Pharmaceuticals PLC | +1.3% | +140.45% | Add |
| 4 | PRAX | Praxis Precision Medicines I | +1.3% | -32.66% | Trim |
| 5 | HROW | Harrow Inc | +1.2% | +139.23% | Add |
| 6 | JAZZ | Jazz Pharmaceuticals plc | +1.1% | +106.13% | Add |
| 7 | RVMD | Revolution Medicines Inc | +1% | +145.41% | Add |
| 8 | CAPR | Capricor Therapeutics Inc | +1% | +24.40% | Add |
| 9 | KOD | Kodiak Sciences Inc | +0.9% | +73.93% | Add |
| 10 | DRUG | Bright Minds Biosciences Inc | +0.9% | +933.12% | Add |
| 11 | SPRB | Spruce Biosciences Inc | +0.8% | +810.26% | Add |
| 12 | RLMD | Relmada Therapeutics Inc | +0.8% | +66.48% | Add |
| 13 | ANRO | Alto Neuroscience Inc | +0.7% | +368.18% | Add |
| 14 | RARE | Ultragenyx Pharmaceutical In | +0.7% | +459.15% | Add |
| 15 | PHVS | Pharvaris N.V. | +0.5% | +131.65% | Add |
| 16 | XBI | Ss Spdr S&p Biotech ETF | +0.5% | +13.33% | Add |
| 17 | RAPT | Rapt Therapeutics Inc | +0.5% | +20.92% | Add |
| 18 | CYTK | Cytokinetics Inc | +0.5% | +38.97% | Add |
| 19 | PTHS | Pelthos Therapeutics Inc | +0.4% | +309.53% | Add |
| 20 | KPTI | Karyopharm Therapeutics Inc | +0.3% | +1897.85% | Add |
| 21 | IVVD | Invivyd Inc | +0.3% | +27.80% | Add |
| 22 | VTYXUSD | Ventyx Biosciences Inc | +0.3% | -26.79% | Trim |
| 23 | SLNOEUR | Soleno Therapeutics Inc | +0.2% | +111.92% | Add |
| 24 | ABVX | Abivax Sa-adr | +0.2% | -16.41% | Trim |
| 25 | PCVX | Vaxcyte Inc | +0.2% | +18.83% | Add |
| 26 | FBRX | Forte Biosciences Inc | +0.2% | — | Unchanged |
| 27 | TENX | Tenax Therapeutics Inc | +0.2% | — | Unchanged |
| 28 | NMRA | Neumora Therapeutics Inc | +0.2% | +10128.90% | Add |
| 29 | MAZE | Maze Therapeutics Inc | +0.2% | -12.98% | Trim |
| 30 | ARVN | Arvinas Inc | +0.1% | +58.34% | Add |
| 31 | PEPG | Pepgen Inc | +0.1% | +39.41% | Add |
| 32 | ADMA | Adma Biologics Inc | +0.1% | +46.92% | Add |
| 33 | IBIO | Ibio Inc | +0.1% | +55.03% | Add |
| 34 | ✓ | Proqr Therapeutics N.v. | +0.1% | +67.25% | Add |
| 35 | TRAW | Traws Pharma Inc | +0.1% | +2280.03% | Add |
| 36 | WVE | Wave Life Sciences Ltd. | 0% | -11.12% | Trim |
| 37 | LYEL | Lyell Immunopharma Inc | 0% | -6.21% | Trim |
| 38 | LXEO | Lexeo Therapeutics Inc | 0% | -9.62% | Trim |
| 39 | ALEC | Alector Inc | 0% | +174.03% | Add |
| 40 | FULC | Fulcrum Therapeutics Inc | 0% | +6.69% | Add |
| 41 | SLN | Silence Therapeutics Plc-adr | 0% | -3.89% | Trim |
| 42 | IOBTQ | Io Biotech Inc | 0% | -9.13% | Trim |
| 43 | 2KZ0 | Kezar Life Sciences Inc | 0% | -4.39% | Trim |
| 44 | HELP | Cybin Inc | — | -5.92% | Trim |
| 45 | ✓ | Immatics NV | — | -1.67% | Trim |
| 46 | VKTX | Viking Therapeutics Inc | — | -2.83% | Trim |
| 47 | LYRA | Lyra Therapeutics Inc | — | — | Unchanged |
| 48 | VYNE | Vyne Therapeutics Inc | — | -8.65% | Trim |
| 49 | EVAX | Evaxion A/s | — | -6.63% | Trim |
| 50 | CMMB | Chemomab Therapeutics LTD | — | -2.76% | Trim |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 148 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CDTX, XBI, AMGN) accounted for 45.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
AMGN
市值: $80.2M
Top Position Liquidated / Trimmed
UTHR
前期市值: $88.9M
During Q4 2025, Ikarian Capital, LLC's top holdings by market value included CDTX (9.9%)、XBI (8.1%)、AMGN (6.3%). The largest single position, CDTX, represented 9.9% of total portfolio value.
In Q4 2025, Ikarian Capital, LLC made 180 total portfolio adjustments, initiating 47 new buys, adding to 33 positions, trimming 62 holdings, and fully liquidating 38 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.